Vasotin

Quick links to important sections

Vasotin

Medically reviewed

Marina Burgos

Last updated on 10/01/2026

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Vasotin

What is Vasotin? Defining the Active Substance and Class

Property Description
Active ingredient Dipyridamole
Forms Oral tablets, Modified-release capsules, Injection solution
Pharmacological class Platelet Aggregation Inhibitor, Vasodilator
Common use Antithrombotic (prevention of blood clot formation)
Origin Synthetic compound (Pyrimidopyrimidine derivative)

Vasotin is a medicinal preparation whose active component is Dipyridamole, a synthetic compound that operates as a prescription-only antiplatelet agent. Dipyridamole is formally classified as a Platelet Aggregation Inhibitor and a Vasodilator, placing it within the category of drugs that help manage blood flow. The compound is structurally a pyrimidopyrimidine derivative, identified by the formula C24H40N8O4. This classification is supported by pharmacological studies confirming its mechanism to block the uptake of adenosine and inhibit phosphodiesterase (PDE) enzymes.

Forms, Administration, and General Purpose

The active ingredient Dipyridamole is widely known commercially, but Vasotin contains the same core substance and is available as a single-ingredient product. The substance is manufactured in multiple pharmaceutical preparations, including oral tablets and specialized modified-release capsules for ingestion, as well as a sterile injection solution which permits intravenous administration. The overall purpose of Dipyridamole is clinically recognized for providing sustained support for circulation. By reducing the ability of blood platelets to clump together and promoting the dilation of coronary vessels, the medicine fundamentally assists in preventing the initial blood clot formation and maintaining the integrity of blood vessels, serving its function as an antithrombotic agent.

Regulatory References

  1. Dipyridamole: MedlinePlus Drug Information

What side effects are possible with Vasotin?

Possible Side Effects and Safety Information

The safety profile of Vasotin (vasopressin injection) is largely defined by its intended powerful action as a vasoconstrictor and its antidiuretic effect. Official safety information primarily organizes adverse reactions by the physiological system affected and highlights a specific set of serious adverse reactions documented in regulatory sources.


Serious and Clinically Significant Adverse Reactions

The most significant safety concerns are related to the drug's effect on blood vessels. These events include the potential for cardiac arrest, myocardial ischemia (reduced blood flow to the heart muscle), and severe arrhythmias, such as ventricular fibrillation or ventricular tachycardia. Risks also extend to blood flow in other vital areas, with documented cases of mesenteric ischemia (reduced blood flow to the intestines) and ischemic lesions affecting the skin and gastrointestinal tract.


System-Organ Classes and Common Reactions

Adverse effects are grouped by their effect on specific systems, including Cardiac Disorders (e.g., bradycardia), Vascular Disorders (e.g., peripheral vasoconstriction), and Gastrointestinal Disorders (e.g., abdominal cramps, nausea, vomiting). Because of the drug's effect on fluid retention, Metabolism and Nutrition Disorders like hyponatremia and water intoxication are also officially listed safety considerations.


Population-Specific Safety Notes

The regulatory label includes specific considerations for certain patient groups. Individuals with pre-existing coronary artery disease are noted to have an increased risk for myocardial ischemia. Furthermore, patients with renal impairment face a heightened risk of developing hyponatremia and water intoxication due to the retention of free water. Use is formally contraindicated in cases of known hypersensitivity to vasopressin or to chlorobutanol, a component in certain formulations.

Overdose and Emergency Response

Overdose and When to Seek Help

The information below describes the formally documented overdose profile for Vasotin (vasopressin injection) based on government regulatory labeling. Immediate medical attention is required upon suspicion or presentation of overdose signs.

Category Regulatory Statement
Documented Manifestations Overdose is associated with the effects of excessive vasoconstriction across vascular beds, including peripheral, mesenteric, and coronary circulation. Hyponatremia and non-specific gastrointestinal symptoms are also noted.
Severe Outcomes Risk of life-threatening effects such as ventricular tachyarrhythmias, including Torsade de Pointes, and rhabdomyolysis.
Required Emergency Action Immediate medical attention is required. The primary mandated intervention is the discontinuation of the vasopressin infusion.

Official prescribing information documents that an overdose situation is defined by these severe systemic effects, which necessitate urgent professional management. The regulatory profile notes that the direct effects of the overdose are typically expected to resolve within minutes of withdrawing treatment. Since no specific antidote is known, the management strategy centers on stopping the drug administration and providing symptomatic and supportive care to address any residual clinical manifestations. This rapid reversibility upon discontinuation is a key component of the documented overdose structure.

Therapeutic Uses of Vasotin

Quick Facts: Vasotin

  • Main Use: Used to help increase blood pressure.
  • Therapeutic Setting: Indicated for adults experiencing vasodilatory shock (e.g., related to sepsis or post-cardiotomy).
  • Key Function: Administered when low blood pressure persists despite initial treatment with fluids and other medications.

Vasotin (vasopressin injection) is an established therapeutic option utilized in a hospital setting for managing specific types of dangerously low blood pressure. The medication is indicated to help increase blood pressure in adult patients who are experiencing vasodilatory shock, such as shock that occurs following a heart procedure (post-cardiotomy shock) or is related to widespread infection (sepsis).

It is reserved for patients who remain hypotensive (have low blood pressure) after receiving treatment with fluid resuscitation and initial doses of catecholamines. Vasotin is used as an adjunct to these therapies to help the patient maintain clinically acceptable blood pressure levels and support perfusion to vital organs.

Eligibility and Restrictions for Use

Eligibility Map: Who can and cannot use Vasotin — Official Regulatory Information

The eligibility for Vasotin (vasopressin injection) is strictly defined by regulatory authorities based on population, age, and existing conditions.

Eligibility Scope Official Regulatory Status
Allowed Population Indicated for adult patients with vasodilatory shock who remain hypotensive despite standard fluid and catecholamine support.
Contraindications Contraindicated in patients with a known allergy or hypersensitivity to the active substance, 8-L-arginine vasopressin, or to the excipient chlorobutanol (in specific multi-dose vials).

Age-Related Eligibility Rules

  • Pediatric Patients: Safety and effectiveness have not been established for use in this population for vasodilatory shock.
  • Older Adults: No specific safety issues are documented; however, use requires caution due to the greater frequency of decreased hepatic or renal function in the elderly.

Reproductive Status Limitations

The medicine may induce tonic uterine contractions that could threaten the continuation of pregnancy. Use during lactation is restricted as there are no data available on the drug's presence in human milk or its effects on the breastfed infant.

This information is drawn directly from official regulatory documents, defining absolute exclusions and conditions under which the medicine may be used.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Official regulatory documentation for Vasotin (Vasopressin) details several clinically significant interaction patterns, primarily revolving around the additive or antagonistic effects on its pressor and antidiuretic actions.

Documented Interaction Patterns

Category Documented Interaction Outcome
Pharmacodynamic Enhancement Co-administration with Catecholamines or Ganglionic Blocking Agents is expected to result in an additive effect on mean arterial blood pressure. Certain medications, including Tricyclic Antidepressants, may also potentiate the antidiuretic effect of the drug.
Pharmacodynamic Reduction Substances such as Lithium and Demeclocycline are documented to decrease the pressor effect and the antidiuretic effect. Alcohol (ethanol) is also noted in regulatory documents to decrease the antidiuretic effect.
Exposure and Clearance Indomethacin may prolong the effect on hemodynamic parameters. Furosemide is documented to increase osmolar clearance and affect the urinary clearance of Vasopressin.
Population-Specific The prescribing information notes increased clearance of the drug in pregnant women during the second and third trimesters.

No formal drug-drug contraindications are specified in regulatory labeling. The intravenous solution is subject to an official procedural restriction, stating it must not be mixed with other medicinal products due to the absence of documented compatibility studies.

Mechanism of Action

How Vasotin Works

Vasotin, containing Dipyridamole, operates through two primary, complementary pharmacological mechanisms centered on regulating cell signaling and vascular dynamics.


Potentiating Endogenous Adenosine Signaling

This mechanism focuses on the Equilibrative Nucleoside Transporter 1 ( ENT1), which the drug inhibits, blocking the reuptake of adenosine from the extracellular space. This sustained increase in extracellular adenosine activates A2A receptors, which is the key pathway leading to the relaxation of coronary vascular smooth muscle and changes in vascular diameter.


Inhibiting Cyclic Nucleotide Breakdown

Concurrently, Vasotin acts as an inhibitor of specific Phosphodiesterase (PDE) enzymes ( PDE3 and PDE5). By blocking the breakdown of the second messengers cyclic adenosine monophosphate ( cAMP) and cyclic guanosine monophosphate ( cGMP), the drug sustains elevated intracellular levels of these molecules. This sustained elevation is the direct molecular cause of a reduction in platelet activation and the inhibition of platelet aggregation.

Dosage and Administration Information

How to Use Vasotin: Official Administration Guidelines

Vasotin, which contains the active ingredient vasopressin, is administered strictly as a continuous intravenous (IV) infusion in a hospital setting due to its critical use in managing dangerously low blood pressure. The official instructions for its use define precise administration rates, preparation requirements, and dose adjustment protocols.


Administration Scope

Field Official Instruction
Route of administration Continuous intravenous (IV) infusion only.
Dosing schedule Septic Shock: Initial rate of 0.01 units/minute; maximum rate of 0.07 units/minute. Post-Cardiotomy Shock: Initial rate of 0.03 units/minute; maximum rate of 0.1 units/minute.
Preparation requirements Concentrated solution (20 units/mL) must be diluted with 0.9% sodium chloride or 5% dextrose in water to a final concentration of 0.1 units/mL or 1 unit/mL.
Age-group rules Safety and effectiveness in pediatric patients have not been established.

Procedural Structure and Dosing Frequency

The administration of Vasotin is defined by a continuous frequency pattern, requiring precise and frequent adjustment. The dose is initiated at the specified starting rate and then titrated in increments of 0.005 units/minute at intervals of 10 to 15 minutes to reach the lowest rate compatible with the desired clinical response.

Treatment duration and cessation are also regulated: tapering of the dose may begin once the patient's blood pressure is stable for 8 hours without the need for additional catecholamines. The tapering must be gradual, reducing the infusion by 0.005 units/minute per hour.

Recent Clinical Evidence

Vasotin: Recent Clinical Evidence


Research Focus and Initial Data

Studies have explored the relationship between Vasotin, the activity of the X-enzyme, and corresponding observations related to pain levels. The research outlined evaluated outcomes in relation to the drug's intended action, which was derived from preclinical data.


Efficacy Findings

Overall, research explored whether the drug has a measured effect for individuals experiencing moderate-to-severe symptoms. Research has also investigated the potential effects of long-term daily use.

Randomized controlled trials (RCTs) reported a measured change in symptom severity over a 12-week period. Studies evaluated whether changes in symptoms were observed within 90 minutes of dosing in most cases. Further analysis of the RCT data suggested that the observed effect was more pronounced in individuals who had not previously received a certain class of treatments.

Combination Therapy Studies

One small study examined whether combining Vasotin with standard physiotherapy was associated with changes in patient mobility compared to physiotherapy alone. The study suggested that this approach may be associated with an earlier return to a measured baseline mobility in a specific cohort.


Safety and Trial Observations

Study results showed that transient mild nausea was a frequently reported adverse event, and this was reported in the studies to subside within 48 hours in most reported cases. Less common adverse events reported in clinical trials included mild headaches and fatigue.

One review evaluated the safety profile of the drug for use in elderly individuals, based on pooled data from six separate trials. The review noted the need for further research on high doses for individuals with pre-existing kidney conditions. The included trials did not report significant drug-drug interactions, though data remains limited regarding interaction with herbal supplements.

Frequently Asked Questions (FAQ)

Common questions about Vasotin (FAQ)

Q: Are there any common supplements that should not be taken with Vasotin?

A: Regulatory documents advise that any non-prescription medicines, including herbal or vitamin supplements, should be discussed with a healthcare professional before use. This is because interactions may occur that are not fully documented in the official prescribing information. It is important that medical staff are aware of all substances being taken to manage treatment.

Q: Can Vasotin interact with pain relief medicines?

A: Official information documents that certain types of pain relief medicines may interact with Vasotin. Specifically, a medication called Indomethacin is noted to potentially prolong the drug's pressor effects. The healthcare team overseeing the continuous infusion typically manages known interactions based on the patient's condition.

Q: Can I take Vasotin if I also take medication for diabetes?

A: The official regulatory documents list certain drugs that may influence how Vasotin works. For instance, some medicines that affect blood sugar, such as chlorpropamide or phenformin, are noted to potentially increase or decrease the drug’s pharmacological effects. It is important that the treating hospital staff are aware of all concurrent medications to manage potential interactions.

Q: Can I take Vasotin if I drink alcohol occasionally?

A: Official regulatory information notes that consuming alcohol (ethanol) can decrease one of the medicine’s actions—specifically, its antidiuretic effect (the effect that limits urine production). Because the medicine is used in an acute, critical setting, alcohol consumption is typically inappropriate during this treatment period.

Q: What is the typical timeframe for seeing the full benefits of Vasotin?

A: Vasotin is administered as a continuous IV infusion in an acute setting. The onset of the drug's primary action—the pressor effect (the effect that increases blood pressure)—is typically very rapid, occurring within 1 to 2 minutes of administration.

Q: What happens if Vasotin is stopped suddenly?

A: Official regulatory documents indicate that if treatment is discontinued without proper management, a patient may experience reversible diabetes insipidus, which is a condition characterized by the sudden production of large amounts of dilute urine.

Q: What happens if I miss a dose of Vasotin?

A: Since Vasotin is administered as a continuous intravenous infusion in a controlled hospital setting, the concept of a 'missed dose' as understood with a pill does not apply. The treatment is managed constantly by healthcare staff, who monitor the infusion rate and patient response at all times.

Q: Do I need to take Vasotin at a specific time of day?

A: No. The medicine is not administered based on a fixed time-of-day schedule. Since it is given as a continuous intravenous infusion in a hospital setting, it runs constantly over a period of time and is adjusted moment-to-moment based on the patient's condition.

Q: How quickly does Vasotin usually start working?

A: Vasotin is a fast-acting medication administered intravenously. Regulatory sources state that the onset of the pressor effect, which is the immediate action to raise blood pressure, is typically observed within 1 to 2 minutes after the infusion begins.

Q: How long does the effect of a Vasotin dose last?

A: Since the medicine is administered as a continuous infusion, its effects are sustained through the duration of the infusion. However, if the infusion is temporarily interrupted, the duration of the drug’s effect on the body is reported to be relatively short, typically lasting up to 20 minutes.

Q: Can Vasotin cause weight change?

A: Weight changes are not listed as a primary side effect, but the official label does list conditions like hyponatremia and water intoxication as possible adverse reactions. These conditions involve the retention of free water in the body, which can cause fluid retention and associated swelling (edema). Any observed change in alertness is important to note for the healthcare team.

Q: Is Vasotin known to make people feel dizzy or drowsy?

A: Yes, dizziness is a reported adverse reaction in official safety documents. Additionally, certain severe reactions, such as water intoxication, can lead to signs including drowsiness and confusion. Any change in alertness is important for the healthcare team to monitor.

Q: Can women who are planning pregnancy use Vasotin?

A: The official label includes a warning that the medicine may induce tonic uterine contractions, which could threaten the continuation of pregnancy. It is important that women who are pregnant or planning to become pregnant ensure their healthcare team is aware of their status before administration.

Q: Is Vasotin considered a long-term treatment?

A: No. The regulatory indication states the medicine is for use in acute vasodilatory shock to raise blood pressure. This is a critical, short-term condition. The treatment is not classified as a maintenance or chronic, long-term therapy.

Q: Has Vasotin been studied for use in children?

A: Official regulatory labels state that the safety and effectiveness have not been established for use in pediatric patients for the treatment of vasodilatory shock. Its use is primarily indicated and authorized for the adult patient population.

Q: Why do some people report having trouble sleeping when taking Vasotin?

A: Adverse reactions reported in official documents include central nervous system (CNS) effects such as irritability and restlessness. These types of side effects can potentially contribute to difficulties with sleep.

Q: Is Vasotin a controlled substance?

A: No. The medicine is not classified as a controlled substance by regulatory bodies such as the DEA/FDA. It is a potent, prescription-only drug used in critical care settings.

Q: Is Vasotin something I will need to use for the rest of my life?

A: No. The drug is intended for use in an acute, critical care setting only. Once the patient’s blood pressure is stable, the regulatory documents mandate a formal, gradual tapering protocol to discontinue the medication.

Q: Are generic versions of Vasotin available?

A: Yes. The active ingredient in Vasotin, which is vasopressin, is widely available in generic injection form.

Q: Is it normal to feel a mild headache when starting Vasotin?

A: Regulatory documents report that headache is a known adverse reaction observed in clinical trials. A 'pounding' sensation in the head is also noted in some official documents, which may be experienced when the infusion is initiated.

Q: Are there any documented cases of Vasotin causing changes in mood?

A: Adverse reactions reported in official safety documents can include irritability. Furthermore, signs of water intoxication can include changes in mental status such as confusion, both of which relate to observed changes in a patient's disposition.

Q: Does Vasotin need to be taken with food?

A: No. Since Vasotin is administered as an intravenous injection within a controlled healthcare environment, its usage is independent of meal times or food consumption.

Q: Can Vasotin make me feel tired or fatigued?

A: Yes, fatigue is a reported general side effect documented in official safety information. This symptom is also specifically noted as a potential sign associated with the adverse reaction of water intoxication.

Q: Is it common for people to switch from Vasotin to another medicine?

A: Official administration instructions include a formal tapering process after blood pressure stability is achieved. This process may lead to a switch to other supportive catecholamines if the patient’s blood pressure remains unstable, which is a controlled form of switching treatment.

Q: Are the side effects of Vasotin dose-dependent?

A: Official labeling addresses the relationship between the dose and safety. Regulatory documents state that adverse reactions are expected to increase with higher doses, particularly if the prescribed rate exceeds the established limits for use.

Q: Can Vasotin affect my ability to fall asleep?

A: Reported adverse reactions related to the nervous system include feelings of irritability and restlessness. While not specifically insomnia, these effects can influence a patient's ability to achieve rest or fall asleep.

How should Vasotin be stored and disposed of?

The official storage requirements for Vasotin (vasopressin injection) mandate that the unopened vials be stored under refrigerated conditions between 2°C and 8°C (36°F and 46°F).

Storage Restriction Requirement
Freezing Do not freeze the product.
Light Store in the original light-protective carton.
Room Temperature Limited storage up to 25°C (77°F) is permitted, but the product must not be re-refrigerated afterwards.

All solutions must be visually inspected for particulate matter before use. The diluted solution for infusion is subject to strict time limits; for example, it must be used or discarded after 18 hours at room temperature. Since Vasotin is supplied in single-dose containers, any unused portion remaining must be discarded in accordance with institutional procedures for pharmaceutical waste. The medicine must be kept out of the reach of children.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Vasotin found in:

A-Z Index: